Tumor spheroid penetration assays, HER2-targeted uptake studies, and prostate-specific membrane antigen (PSMA) binding assays confirm their specificity in reaching tumor cells [6,9,11,12,14,50,60,71,83,84,118]. This evidence concerns the gene FOLH1 and neoplasm.